Perampanel (Fycompa®) is recommended as an option for restricted use within NHS Wales. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Perampanel (Fycompa®) should be restricted to treatment of patients whose seizures are still uncontrolled with first adjunctive therapy, within its licensed indication as adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Perampanel (Fycompa®) is not recommended for use within NHS Wales outside of this subpopulation.